Lin Wang is an accomplished director at Gilead Sciences, with extensive experience in CMC analytical leadership from pre-clinical to commercial stages. Since April 2017, Lin Wang has overseen small molecule and peptide analytical development for multiple drug combinations across various dosage forms. Prior to Gilead Sciences, Lin Wang held several positions at Merck from October 2012 to March 2017, culminating in a role as Principal Scientist/Group Leader, leading analytical activities from Lead Optimization to Commercialization. Lin Wang began a career at Eli Lilly and Company from January 2007 to September 2012, where contributions included leading projects in Local China Development and developing phase-appropriate analytical control strategies. Lin Wang holds a PhD in Analytical Chemistry from the University of Florida, earned in December 2006.
This person is not in the org chart
This person is not in any teams
This person is not in any offices